CoChat

Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial

Open access
Pagidipati, Neha J., Nelson, Adam J., Kaltenbach, Lisa A., Leyva, Monica, McGuire, Darren K., Pop-Busui, Rodica, Cavender, Matthew A., Aroda, Vanita R., Magwire, Melissa L., Richardson, Caroline R., Lingvay, Ildiko, Kirk, Julienne K., Al-Khalidi, Hussein R., Webb, Laura, Gaynor, Tanya, Pak, Jonathan, Senyucel, Cagri, Lopes, Renato D., Green, Jennifer B., Granger, Christopher B., COORDINATE–Diabetes Site Investigators, Kumar, Priya, Mahal, Sharan, Javier, Julian, Purdy, Drew, Ahmed, Syed, Schmidt, Dwayne, Sharma, Saurabh, Salacata, Abraham, Covalesky, John, Paraschos, Alexander, Cohan, Kenneth, Walia, Jasjit, Ranadive, Nandkishore, Flood, Roy, Friedman, Keith, Bayron, Carlos, Weston, Patrick, Adler, Alexander, Viswanath, Dilip, Calhoun, Linda, Khandelwal, Abha, Cohen, Michael, Zarich, Stuart, Gianos, Eugenia, Korabathina, Ravikiran, Mehta, Rajendra, Hochrein, James, Arora, Vikram, Cruz, Jairo, Pacheco-Coronado, Roberto, Kelly, Jacob, Garg, Rajesh, Ogunniyi, Modele, Weinberg, Matthew, Davuluri, Ashwini, Danciu, Sorin, Almousalli, Omar, Bellamkonda, Pallavi, Nwakile, Chinaulumogu, Sokolowicz, John, Martin, Enrico, Kerut, Kennety, Pandey, Amabrish, Vijay, Nampalli, Bui, Hanh, Khan, Waqar, Morrow, Michael, Prashad, Rakesh, Bruemmer, Dennis · 2023 · JAMA
Cited by 105

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Importance: Evidence-based therapies to reduce atherosclerotic cardiovascular disease risk in adults with type 2 diabetes are underused in clinical practice. Objective: To assess the effect of a coordinated, multifaceted intervention of assessment, education, and feedback vs usual care on the proportion of adults with type 2 diabetes and atherosclerotic cardiovascular disease prescribed all 3 groups of recommended, evidence-based therapies (high-intensity statins, angiotensin-converting enzyme inhibitors [ACEIs] or angiotensin receptor blockers [ARBs], and sodium-glucose cotransporter 2 [SGLT2] inhibitors and/or glucagon-like peptide 1 receptor agonists [GLP-1RAs]). Design, Setting, and Participants: Cluster randomized clinical trial with 43 US cardiology clinics recruiting participants from July 2019 through May 2022 and follow-up through December 2022. The participants were adults with type 2 diabetes and atherosclerotic cardiovascular disease not already taking all 3 groups of evidence-based therapies. Interventions: Assessing local barriers, developing care pathways, coordinating care, educating clinicians, reporting data back to the clinics, and providing tools for participants (n = 459) vs usual care per practice guidelines (n = 590). Main Outcomes and Measures: The primary outcome was the proportion of participants prescribed all 3 groups of recommended therapies at 6 to 12 months after enrollment. The secondary outcomes included changes in atherosclerotic cardiovascular disease risk factors and a composite outcome of all-cause death or hospitalization for myocardial infarction, stroke, decompensated heart failure, or urgent revascularization (the trial was not powered to show these differences). Results: Of 1049 participants enrolled (459 at 20 intervention clinics and 590 at 23 usual care clinics), the median age was 70 years and there were 338 women (32.2%), 173 Black participants (16.5%), and 90 Hispanic participants (8.6%). At the last follow-up visit (12 months for 97.3% of participants), those in the intervention group were more likely to be prescribed all 3 therapies (173/457 [37.9%]) vs the usual care group (85/588 [14.5%]), which is a difference of 23.4% (adjusted odds ratio [OR], 4.38 [95% CI, 2.49 to 7.71]; P < .001) and were more likely to be prescribed each of the 3 therapies (change from baseline in high-intensity statins from 66.5% to 70.7% for intervention vs from 58.2% to 56.8% for usual care [adjusted OR, 1.73; 95% CI, 1.06-2.83]; ACEIs or ARBs: from 75.1% to 81.4% for intervention vs from 69.6% to 68.4% for usual care [adjusted OR, 1.82; 95% CI, 1.14-2.91]; SGLT2 inhibitors and/or GLP-1RAs: from 12.3% to 60.4% for intervention vs from 14.5% to 35.5% for usual care [adjusted OR, 3.11; 95% CI, 2.08-4.64]). The intervention was not associated with changes in atherosclerotic cardiovascular disease risk factors. The composite secondary outcome occurred in 23 of 457 participants (5%) in the intervention group vs 40 of 588 participants (6.8%) in the usual care group (adjusted hazard ratio, 0.79 [95% CI, 0.46 to 1.33]). Conclusions and Relevance: A coordinated, multifaceted intervention increased prescription of 3 groups of evidence-based therapies in adults with type 2 diabetes and atherosclerotic cardiovascular disease. Trial Registration: ClinicalTrials.gov Identifier: NCT03936660

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2023.2854

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 16

  1. Foulquier, 2014, Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis., J Hypertens, 32, 1334, 10.1097/HJH.0000000000000154 · DOI
  2. Nelson, 2021, Gaps in evidence-based therapy use in insured patients in the United States with type 2 diabetes mellitus and atherosclerotic cardiovascular disease., J Am Heart Assoc, 10, 10.1161/JAHA.120.016835 · DOI · Paper page
  3. Nelson, 2023, Coordinating Cardiology clinics randomized trial of interventions to improve outcomes (COORDINATE)—diabetes: rationale and design., Am Heart J, 256, 2, 10.1016/j.ahj.2022.10.079 · DOI
  4. Mallinckrodt, 2004, Choice of the primary analysis in longitudinal clinical trials., Pharm Stat, 3, 161, 10.1002/(ISSN)1539-1612 · DOI
  5. Kaplan, 1958, Nonparametric estimation from incomplete observations., J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452 · DOI · Paper page
  6. Austin, 2017, A tutorial on multilevel survival analysis: methods, models and applications., Int Stat Rev, 85, 185, 10.1111/insr.v85.2 · doi:10.1111/insr.v85.2
  7. Vinereanu, 2017, A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial., Lancet, 390, 1737, 10.1016/S0140-6736(17)32165-7 · DOI · Paper page
  8. Chan, 2017, ACC/AHA special report: clinical practice guideline implementation strategies: a summary of systematic reviews by the NHLBI Implementation Science Work Group: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines., Circulation, 135, e122, 10.1161/CIR.0000000000000481 · DOI · Paper page
  9. Wang, 2019, Effect of medication co-payment vouchers on P2Y12 inhibitor use and major adverse cardiovascular events among patients with myocardial infarction: the ARTEMIS randomized clinical trial., JAMA, 321, 44, 10.1001/jama.2018.19791 · DOI
  10. Choudhry, 2011, Full coverage for preventive medications after myocardial infarction., N Engl J Med, 365, 2088, 10.1056/NEJMsa1107913 · DOI · Paper page
  11. Adusumalli, 2023, Effect of nudges to clinicians, patients, or both to increase statin prescribing: a cluster randomized clinical trial., JAMA Cardiol, 8, 23, 10.1001/jamacardio.2022.4373 · DOI
  12. Ghazi, 2022, Electronic alerts to improve heart failure therapy in outpatient practice: a cluster randomized trial., J Am Coll Cardiol, 79, 2203, 10.1016/j.jacc.2022.03.338 · DOI · Paper page
  13. Allen, 2021, An electronically delivered patient-activation tool for intensification of medications for chronic heart failure with reduced ejection fraction: the EPIC-HF trial., Circulation, 143, 427, 10.1161/CIRCULATIONAHA.120.051863 · DOI · Paper page
  14. Blood, 2023, Results of a remotely delivered hypertension and lipid program in more than 10?000 patients across a diverse health care network., JAMA Cardiol, 8, 12, 10.1001/jamacardio.2022.4018 · DOI · Paper page
  15. Thomas, 2021, Cardiometabolic center of excellence: a novel care delivery model for secondary prevention of cardiovascular disease in type 2 diabetes., Circ Cardiovasc Qual Outcomes, 14, 10.1161/CIRCOUTCOMES.120.007682 · DOI · Paper page
  16. Neeland, 2022, Lessons learned from a patient-centered, team-based intervention for patients with type 2 diabetes at high cardiovascular risk: year 1 results from the CINEMA program., J Am Heart Assoc, 11, 10.1161/JAHA.120.024482 · DOI

Cited by

See all 105

Metadata

Authors
Pagidipati, N. J., Nelson, A. J., Kaltenbach, L. A., Leyva, M., McGuire, D. K., Pop-Busui, R., Cavender, M. A., Aroda, V. R., Magwire, M. L., Richardson, C. R., Lingvay, I., Kirk, J. K., Al-Khalidi, H. R., Webb, L., Gaynor, T., Pak, J., Senyucel, C., Lopes, R. D., Green, J. B., Granger, C. B., COORDINATE–Diabetes Site Investigators, Kumar, P., Mahal, S., Javier, J., Purdy, D., Ahmed, S., Schmidt, D., Sharma, S., Salacata, A., Covalesky, J., Paraschos, A., Cohan, K., Walia, J., Ranadive, N., Flood, R., Friedman, K., Bayron, C., Weston, P., Adler, A., Viswanath, D., Calhoun, L., Khandelwal, A., Cohen, M., Zarich, S., Gianos, E., Korabathina, R., Mehta, R., Hochrein, J., Arora, V., Cruz, J., Pacheco-Coronado, R., Kelly, J., Garg, R., Ogunniyi, M., Weinberg, M., Davuluri, A., Danciu, S., Almousalli, O., Bellamkonda, P., Nwakile, C., Sokolowicz, J., Martin, E., Kerut, K., Pandey, A., Vijay, N., Bui, H., Khan, W., Morrow, M., Prashad, R., & Bruemmer, D.
Venue
JAMA
Published
2023-04-18
Volume
329
Issue
15
Pages
1261
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W4323293774
Cited by
105
References
10
FWCI
17.37
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2023.2854
The paper
Pagidipati, N. J., Nelson, A. J., Kaltenbach, L. A., Leyva, M., McGuire, D. K., Pop-Busui, R., Cavender, M. A., Aroda, V. R., Magwire, M. L., Richardson, C. R., Lingvay, I., Kirk, J. K., Al-Khalidi, H. R., Webb, L., Gaynor, T., Pak, J., Senyucel, C., Lopes, R. D., Green, J. B., . . . Bruemmer, D. (2023). Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2023.2854

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.